Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07271667 · ClinicalTrials.gov registry record · Phase 2
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
A Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies, sponsored by Curis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT07271667 is a Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies that is actively recruiting participants, run by Curis. The registered enrollment target is 108 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07271667, a Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies, is actively recruiting participants, sponsored by Curis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Emavusertib
Study Locations (1)
Florida
- Mt Sinai Comprehensive Cancer Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07271667
The ClinicalTrials.gov registry entry for NCT07271667 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT07271667 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07271667 about?
NCT07271667 is a clinical study titled "A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies". The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
What is the current status of trial NCT07271667?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2026-02. Estimated completion is 2027-11.
What conditions does trial NCT07271667 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, B-cell Malignancies.
What interventions are being tested in trial NCT07271667?
The interventions under investigation include: Zanubrutinib (DRUG), Emavusertib (DRUG).
Who is sponsoring clinical trial NCT07271667?
This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07271667 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.